Fasted serum FGF-19 levels are reduced in individuals with overweight, obesity, and NAFLD and it has even been suggested as a diagnostic biomarker for NASH [17]. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatotic liver disease.